Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis
Sofie Vaengebjerg, Lone Skov, Alexander Egeberg, et al.
JAMA Dermatology (2020) Vol. 156, Iss. 4, pp. 421-421
Open Access | Times Cited: 174

Showing 1-25 of 174 citing articles:

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations
Alexander Nast, Catherine Smith, Phyllis I. Spuls, et al.
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 35, Iss. 2, pp. 281-317
Open Access | Times Cited: 146
Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review
Jin Bu, Rui‐Lian Ding, Liang-Jia Zhou, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 145
Signaling pathways and targeted therapies for psoriasis
Jia Guo, H. Zhang, Wenrui Lin, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 132
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials
Mark Lebwohl, Richard B. Warren, Howard Sofen, et al.
British Journal of Dermatology (2024) Vol. 190, Iss. 5, pp. 668-679
Open Access | Times Cited: 28
Biologics for Psoriasis
A. Mitchel Wride, Gloria F. Chen, Sarah L. Spaulding, et al.
Dermatologic Clinics (2024) Vol. 42, Iss. 3, pp. 339-355
Closed Access | Times Cited: 17
The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: A systematic analysis from the Global Burden of Disease Study 2017
Sino Mehrmal, Prabhdeep Uppal, Natalie Nedley, et al.
Journal of the American Academy of Dermatology (2020) Vol. 84, Iss. 1, pp. 46-52
Open Access | Times Cited: 101
Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches
Anna Campanati, Andrea Marani, Emanuela Martina, et al.
Biomedicines (2021) Vol. 9, Iss. 11, pp. 1511-1511
Open Access | Times Cited: 80
Formulating research questions for evidence-based studies
Mohammad‐Salar Hosseini, Farid Jahanshahlou, Mohammad Amin Akbarzadeh, et al.
Journal of Medicine Surgery and Public Health (2023) Vol. 2, pp. 100046-100046
Open Access | Times Cited: 39
Immune-mediated inflammatory diseases: Common and different pathogenic and clinical features
Giovanni Monteleone, A. Moscardelli, Alice Colella, et al.
Autoimmunity Reviews (2023) Vol. 22, Iss. 10, pp. 103410-103410
Open Access | Times Cited: 34
Use of methotrexate and risk of skin cancer: a nationwide case–control study
Sam Polesie, Martin Gillstedt, Sigrún Alba Jóhannesdóttir Schmidt, et al.
British Journal of Cancer (2023) Vol. 128, Iss. 7, pp. 1311-1319
Open Access | Times Cited: 29
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis
Bruce Strober, Laura C. Coates, Mark Lebwohl, et al.
Drug Safety (2023) Vol. 47, Iss. 1, pp. 39-57
Open Access | Times Cited: 27
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open‐label, phase 3 trial
Shinichi Imafuku, Yukari Okubo, Yayoi Tada, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 3, pp. 365-379
Open Access | Times Cited: 16
Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database
Vishnu Eshwar, Ashwin Kamath
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study
Teresa Battista, Lucia Gallo, Fabrizio Martora, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 7, pp. 1940-1940
Open Access | Times Cited: 9
Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis)
Mario Valenti, Luciano Ibba, S. Di Giulio, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access | Times Cited: 1
cPLA2 blockade attenuates S100A7-mediated breast tumorigenicity by inhibiting the immunosuppressive tumor microenvironment
Sanjay Mishra, Manish Charan, Rajni Kant Shukla, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 35
Psoriasis may increase the risk of lung cancer: a two‐sample Mendelian randomization study
Qiang Luo, Jida Chen, Lang Qin, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 11, pp. 2113-2119
Closed Access | Times Cited: 32
A Review of the Safety of Interleukin-17A Inhibitor Secukinumab
Vishnu Eshwar, Ashwin Kamath, Rajeshwari Shastry, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 11, pp. 1365-1365
Open Access | Times Cited: 30
Psoriasis and skin cancer – Is there a link?
A. C. Balda, Irshad Wani, Tamsheel Fatima Roohi, et al.
International Immunopharmacology (2023) Vol. 121, pp. 110464-110464
Closed Access | Times Cited: 20
Association between psoriasis and lung cancer: two-sample Mendelian randomization analyses
Xiuqing Wang, Xiulan Wang, Wang Hongkang, et al.
BMC Pulmonary Medicine (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 18
Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade
Julia Holzgruber, Christina Martins, Zsófi Kulcsár, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
Multimorbidity of Psoriasis: A Large-Scale Population Study of Its Associated Comorbidities
Manuel Almenara‐Blasco, Tamara Gracia‐Cazaña, Beatriz Poblador‐Plou, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 492-492
Open Access | Times Cited: 7
Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials
Atul Deodhar, Andrew Blauvelt, Mark Lebwohl, et al.
Arthritis Research & Therapy (2024) Vol. 26, Iss. 1
Open Access | Times Cited: 7
Psoralen: a narrative review of current and future therapeutic uses
Panagis Galiatsatos, Daniella D. Maydan, Elle Macalpine, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 3
Open Access | Times Cited: 7
Examining the causal association between psoriasis and bladder cancer: A two‐sample Mendelian randomization analysis
Lihuan Du, Bohan Wang, Jiaming Wen, et al.
Skin Research and Technology (2024) Vol. 30, Iss. 4
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top